Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences (ARTL) reported nonclinical data showing once-daily oral ART27.13 achieved approximately 20% body-weight loss over four weeks in obese mice, comparable to semaglutide monotherapy.
In a diet‑induced obesity model, combining ART27.13 with semaglutide led to about 40% weight loss, roughly double that of either agent alone and reducing weight to that of lean controls. Around 80% of weight lost with ART27.13 (alone or in combination) and about 70% with semaglutide alone was fat, with lean mass and body fat normalized to lean animals and the largest effects in the combination group.
ART27.13 showed no effect on weight, fat, or lean mass in lean mice and maintained reduced weight even as food intake recovered. Metabolic markers such as liver hypertrophy, cholesterol, and glucose handling were favorable with ART27.13, particularly in combination, supporting its description as a peripherally acting dual CB1/CB2 agonist with a potential “metabolic regulator” profile.
Artelo Biosciences (ARTL) will present at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14‑16, 2026, at the Lotte New York Palace Hotel in New York City. CEO Gregory D. Gorgas will deliver a company presentation available online from September 11, 2026 at 7:00 a.m. Eastern Time, and management will hold one‑on‑one meetings with qualified investors during the conference.
Artelo Biosciences (Nasdaq: ARTL) has approved a 1-for-9 reverse stock split of its common stock, with trading on a split-adjusted basis on the Nasdaq Capital Market expected to begin at market open on August 31, 2026. The Reverse Split is intended to increase the price per share to improve marketability and liquidity. Each nine issued and outstanding common shares will be automatically combined into one share, with no fractional shares issued; any fractional entitlement will be rounded up to one whole share. According to Artelo, shareholder pro-rata ownership will be unchanged, all outstanding warrants and other derivatives will adjust per their terms, and approximately 547,774 common shares will be outstanding immediately after effectiveness.
Artelo Biosciences (Nasdaq: ARTL) reported that the Japanese Patent Office issued a notification of allowance with a Decision to Grant for patent claims covering the intended commercial formulation of ART27.13, a peripherally selective dual cannabinoid agonist dispersed in polyethylene glycol.
The allowed claims align with those in the United States and Europe, with all three jurisdictions expected to provide protection through 2041, strengthening ART27.13’s global intellectual property position. ART27.13 is in two Phase 2 trials: CAReS in cancer-related anorexia, which has shown early weight-stabilizing signals, and DREAM in glaucoma or ocular hypertension, with initial results anticipated in the fourth quarter.
Artelo Biosciences (Nasdaq: ARTL) reported that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering the intended commercial formulation of ART27.13, its peripherally selective cannabinoid agonist. The allowed claims cover compositions of ART27.13 dispersed in polyethylene glycol and are expected to extend patent protection for ART27.13 in the United States through 2041, supporting the company’s long-term intellectual property strategy.
ART27.13 is in two Phase 2 studies: the CAReS trial for cancer-related anorexia and the DREAM study in glaucoma or ocular hypertension. According to Artelo Biosciences, Phase 1 data showed good tolerability and early signs of stabilizing or reversing weight loss in over 60% of participants, while interim Phase 2 CAReS results showed reversal of cancer-related anorexia in all patients on the highest dose, with placebo patients continuing to lose weight. The DREAM Phase 2 study, funded by Glaucoma UK and the HSC R&D Division, is assessing once-daily oral ART27.13 to reduce intraocular pressure, with initial results anticipated in the fourth quarter of this year.
Artelo Biosciences (Nasdaq: ARTL) reported second quarter 2026 results and pipeline progress. The company is preparing a Phase 1 multiple ascending dose study of ART26.12 in Q4 2026 after favorable first-in-human safety, pharmacokinetics, and metabolite profiling data supporting chronic pain development.
ART27.13 showed encouraging interim Phase 2 CAReS outcomes in body weight, lean mass and activity, plus nonclinical neuropathy pain data, alongside a fully funded Phase 2 glaucoma study. ART12.11 advanced preclinical work, supported by a CBD literature review. Artelo completed an $11.0 million financing. Q2 2026 R&D was $0.9 million, G&A $1.6 million, net loss $2.4 million, with $4.2 million in cash and investments as of June 30, 2026.
Artelo Biosciences (Nasdaq: ARTL) reported that the first patient has been dosed in the Phase 2 DREAM study, which is evaluating its orally administered synthetic cannabinoid ART27.13 in patients with glaucoma or ocular hypertension. ART27.13 is described as a peripherally selective cannabinoid receptor agonist intended to modulate intraocular pressure (IOP) via receptors in ocular tissues.
The investigator-led study is funded by Glaucoma UK and the HSC R&D Division, sponsored by the Belfast Health and Social Care Trust, and conducted by the Northern Ireland Clinical Trials Unit. It is led by glaucoma specialist Professor Augusto Azuara-Blanco of Queen’s University Belfast. According to Artelo, initial DREAM results are anticipated in Q4 2026, potentially expanding ART27.13’s clinical reach into ophthalmology amid ongoing unmet need for safe, well-tolerated IOP-lowering therapies.
Artelo Biosciences (Nasdaq: ARTL) reported that a peer-reviewed review article, led by an Artelo scientist and now published in the British Journal of Clinical Pharmacology, evaluated over 50 studies of low-dose cannabidiol (CBD) typical of over-the-counter products.
The review found that CBD doses ≤2.5 mg/kg or ≤175 mg/day generally produced little to no evidence of biological or therapeutic effect, with plasma exposures 5–100 times lower than therapeutic epilepsy doses. It also identified significant drug-drug interactions with common medications. According to Artelo, these data highlight formulation and delivery limitations and support the rationale for its proprietary CBD cocrystal, ART12.11, which has shown higher CBD plasma levels in preclinical studies and is being advanced toward clinical development.
Artelo Biosciences (Nasdaq: ARTL) reported new nonclinical data showing its selective FABP5 inhibitor ART26.12 reduced osteoarthritis (OA)-associated pain behaviors after acute and chronic oral dosing over four weeks, with efficacy described as comparable to naproxen, a widely used NSAID in OA.
According to Artelo, ART26.12 produced distinct changes in endocannabinoids and related bioactive lipids versus naproxen, supporting a novel mechanism of action. Animals receiving ART26.12 showed significantly less stomach tissue damage, including non-glandular hyperkeratosis, suggesting potential for an improved gastrointestinal safety profile relative to naproxen in this model.
The company stated that these data expand ART26.12’s potential utility beyond neuropathic pain into OA and broader chronic pain conditions. Preparations are underway for a multiple ascending repeat dose study in healthy volunteers, with enrollment anticipated to begin in the fourth quarter of this year.
Artelo Biosciences (Nasdaq: ARTL) reminded shareholders to vote their shares in advance of its virtual Annual Meeting of Shareholders scheduled for July 17, 2026. The company urges all shareholders of record, regardless of holdings size, to promptly submit proxies using the methods described in previously distributed proxy materials.
According to Artelo Biosciences, every proxy, whether voting FOR, AGAINST, or ABSTAIN on proposals, helps establish the required quorum so the meeting’s business can proceed. Failure to achieve a quorum could force adjournment and reconvening, increasing the company’s expenses and administrative effort.